Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation.

Wang AM, Miyata Y, Klinedinst S, Peng HM, Chua JP, Komiyama T, Li X, Morishima Y, Merry DE, Pratt WB, Osawa Y, Collins CA, Gestwicki JE, Lieberman AP.

Nat Chem Biol. 2013 Feb;9(2):112-8. doi: 10.1038/nchembio.1140. Epub 2012 Dec 9.

2.

Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation.

Wang AM, Morishima Y, Clapp KM, Peng HM, Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP.

J Biol Chem. 2010 May 21;285(21):15714-23. doi: 10.1074/jbc.M109.098806. Epub 2010 Mar 26.

3.

Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein.

Adachi H, Katsuno M, Minamiyama M, Sang C, Pagoulatos G, Angelidis C, Kusakabe M, Yoshiki A, Kobayashi Y, Doyu M, Sobue G.

J Neurosci. 2003 Mar 15;23(6):2203-11.

4.

Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases.

Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP.

Annu Rev Pharmacol Toxicol. 2015;55:353-71. doi: 10.1146/annurev-pharmtox-010814-124332. Epub 2014 Sep 25. Review.

5.

Pharmacological tuning of heat shock protein 70 modulates polyglutamine toxicity and aggregation.

Chafekar SM, Wisén S, Thompson AD, Echeverria A, Walter GM, Evans CG, Makley LN, Gestwicki JE, Duennwald ML.

ACS Chem Biol. 2012 Sep 21;7(9):1556-64. Epub 2012 Jun 22.

6.
7.

Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy.

Beauchemin AM, Gottlieb B, Beitel LK, Elhaji YA, Pinsky L, Trifiro MA.

Brain Res Bull. 2001 Oct-Nov 1;56(3-4):285-97.

PMID:
11719263
8.

Disrupting SUMOylation enhances transcriptional function and ameliorates polyglutamine androgen receptor-mediated disease.

Chua JP, Reddy SL, Yu Z, Giorgetti E, Montie HL, Mukherjee S, Higgins J, McEachin RC, Robins DM, Merry DE, Iñiguez-Lluhí JA, Lieberman AP.

J Clin Invest. 2015 Feb;125(2):831-45. doi: 10.1172/JCI73214. Epub 2015 Jan 20.

9.

Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.

Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Doyu M, Sobue G.

J Mol Med (Berl). 2006 Aug;84(8):635-46. Epub 2006 Jun 2. Review.

PMID:
16741751
10.

Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction.

Thomas M, Harrell JM, Morishima Y, Peng HM, Pratt WB, Lieberman AP.

Hum Mol Genet. 2006 Jun 1;15(11):1876-83. Epub 2006 Apr 27.

PMID:
16644868
11.

Intercellular chaperone transmission via exosomes contributes to maintenance of protein homeostasis at the organismal level.

Takeuchi T, Suzuki M, Fujikake N, Popiel HA, Kikuchi H, Futaki S, Wada K, Nagai Y.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):E2497-506. doi: 10.1073/pnas.1412651112. Epub 2015 Apr 27.

12.

Protein arginine methyltransferase 6 enhances polyglutamine-expanded androgen receptor function and toxicity in spinal and bulbar muscular atrophy.

Scaramuzzino C, Casci I, Parodi S, Lievens PM, Polanco MJ, Milioto C, Chivet M, Monaghan J, Mishra A, Badders N, Aggarwal T, Grunseich C, Sambataro F, Basso M, Fackelmayer FO, Taylor JP, Pandey UB, Pennuto M.

Neuron. 2015 Jan 7;85(1):88-100. doi: 10.1016/j.neuron.2014.12.031.

13.

Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones.

Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T.

J Biol Chem. 2008 Sep 19;283(38):26188-97. doi: 10.1074/jbc.M710521200. Epub 2008 Jul 16.

14.

Fighting polyglutamine disease by wrestling with SUMO.

Craig TJ, Henley JM.

J Clin Invest. 2015 Feb;125(2):498-500. doi: 10.1172/JCI80278. Epub 2015 Jan 20.

15.

Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system.

Brychzy A, Rein T, Winklhofer KF, Hartl FU, Young JC, Obermann WM.

EMBO J. 2003 Jul 15;22(14):3613-23.

16.

Hsp105alpha suppresses the aggregation of truncated androgen receptor with expanded CAG repeats and cell toxicity.

Ishihara K, Yamagishi N, Saito Y, Adachi H, Kobayashi Y, Sobue G, Ohtsuka K, Hatayama T.

J Biol Chem. 2003 Jul 4;278(27):25143-50. Epub 2003 Apr 24.

17.

A model in which heat shock protein 90 targets protein-folding clefts: rationale for a new approach to neuroprotective treatment of protein folding diseases.

Pratt WB, Morishima Y, Gestwicki JE, Lieberman AP, Osawa Y.

Exp Biol Med (Maywood). 2014 Nov;239(11):1405-13. doi: 10.1177/1535370214539444. Epub 2014 Jul 2. Review.

18.

The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities.

Hageman J, van Waarde MA, Zylicz A, Walerych D, Kampinga HH.

Biochem J. 2011 Apr 1;435(1):127-42. doi: 10.1042/BJ20101247.

PMID:
21231916
19.

Novel mechanism of Hsp70 chaperone-mediated prevention of polyglutamine aggregates in a cellular model of huntington disease.

Guzhova IV, Lazarev VF, Kaznacheeva AV, Ippolitova MV, Muronetz VI, Kinev AV, Margulis BA.

Hum Mol Genet. 2011 Oct 15;20(20):3953-63. doi: 10.1093/hmg/ddr314. Epub 2011 Jul 20.

PMID:
21775503
20.

Supplemental Content

Support Center